K-111 is a PPAR-alpha agonist with potential for treating type 2 diabetes mellitus and hyperlipidemia. It improves insulin resistance, reduces body weight, and ameliorates atherogenic dyslipidemia, with preliminary evidence indicating low toxicity and minimal adverse effects.
Usually ships within 24 hours.